A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma
| Title | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
|---|---|
| Description | The study will submit its CSR data to Health Authority of Australia. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA013451 |
| Release Date | 2022-12-31 |
| Submitter | Xiaoxiao Wang (mandy.wang@bms.com) |
| Organization | Bristol-Myers Squibb (China) Investment Co., Ltd. |
| Submission Date | 2022-11-24 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002451-01 | CA209-459 Backup Dataset | 110 | Biomarker Data | 11.0 MB | rar | 0 | Controlled |